SUMMARY The monoclonal antibody NK1 C3, synthesised by the Netherlands Cancer Institute, has been used to assess its value in the diagnosis of melanocytic lesions. The antigen recognised by this antibody is not denatured by formalin fixation, with the result that the antibody can be used for retrospective studies on conventionally processed material.
In the past three years a large number of monoclonal antibodies have been raised against melanoma cells. Most have been raised against short term cell lines, or membrane fractions, and as a result tend to react with surface membrane antigens. These are often disrupted or destroyed by conventional histological fixation and preparation techniques, and as a result the antibodies react only with fresh frozen tissue. This is obviously a major disadvantage as far as routine surgical pathology is concerned, in that no retrospective studies on an unexpectedly pleomorphic tissue can be performed. Although the practice of surgeons and pathologists is evolving to utilise the "new morphology," with reservation of a small portion of frozen tissue for such work, those who work with primary malignant melanoma are understandably reluctant to divide up a specimen in such a way that the Breslow thickness measurement may be inaccurate. This problem does Accepted for publication 15 December 1983 not arise when one is dealing with a large tumour sample, but it does arise with small primary lesions in which the diagnosis is not clinically apparent.
In this paper we report our experience with the use of the NK1 C3 monoclonal antibody as an aid to the diagnosis of melanocytic lesions. It does not discriminate between benign and malignant melanocytic lesions, but it does show a useful level of specificity for melanocytic versus non-melanocytic lesions.
Material and methods
The monoclonal antibody NK1 C3 was made available to us by Dr C Vennegoor and Dr P Rumke, to whom we express our gratitude. Details of the synthesis and characterisation have already been published.' Briefly, plasma membrane fractions of the human melanoma line Me Wo were used to immunise BALB-C mice, and spleen cells were then fused with the murine myeloma line P3 X 63 Ag 8. 367 
Results
These are listed in Table 1 for melanocytic lesions  and Table 2 In the primary melanomata the antibody identified cells admixed with lymphocytes in the infiltrate which often occupies these lesions. This permitted more accurate measurements of Breslow thickness, and comparison of the measurement using haematoxylin and eosin stained sections with that using antibody stained sections indicated that both overestimates and underestimates were made of Breslow thickness in haematoxylin and eosin stained sections. In lesions with dense underlying infiltrates the Breslow thickness measurement tended to be falsely thick as the deepest inflammatory cell was often measured: in contrast, in lesions with a mild and desultory scattered infiltrate the tendency was to produce a falsely thin measurement and ignore isolated infiltrating tumour cells. The problem is illustrated in Fig. 2 . 
BENIGN MELANOCYTIC LESIONS
Of 69 benign melanocytic tumours studied, 55 were positive. Eleven of the negative sections were from Spitz naevi, and three from intradermal naevi. This is of interest with regard to the ontogeny of the Spitz MacKie, Campbell, Turbitt lesion and may be of some value in the difficult differentiation between Spitzoid malignant melanoma and true Spitz naevus. If positive, the lesion may be either tumour, but a negative result would be supportive evidence in favour of a benign lesion.
Strength of staining was variable in all the benign melanocytic lesions, both within a lesion and between different cells and lesions of the same histological type. In general, intradermal naevi were lightly stained, while junctional and dysplastic naevi showed strong staining. This was not, however, constant enough to be utilised in diagnosis.
In 13 cases (six melanoma and seven naevi) it was possible to compare the staining pattern of NK1 C3 in frozen and paraffin processed samples from the same piece of tissue. In all cases the staining pattern was clearer and stronger on paraffin processed tissue. This is an unusual observation in the case of a monoclonal antibody, but clearly is an advantage for retrospective studies. (Table 2) The non-melanocytic tumours were chosen for their importance to the dermatopathologist (squamous carcinoma, basal cell carcinoma, and appendage tumours-group 1); for the ontogenetical relation to melanocytes (neural tumours-group 2); and for their importance in the diagnosis of anaplastic tumour masses presenting as secondary tumours of unknown derivation (gastrointestinal, breast, or prostatic tumours and lymphomata-group 3). The antibody showed no reactivity with either group 1 or group 2 tumours, but did show reactivity with some of the group 3 tumours. These were breast, with 2/6 positive results, and prostate, with 2/5 positive results. Other tumours tested in this section were negative, but obviously a wider range of nonmelanocytic tumours would be required to establish the exact cross reactivity of this antibody. It is relatively rare for a dermatopathologist to have diagnostic difficulties between tumours included in group 1, but during the course of the study one such example arose. A 68 year old man was referred with a red nodule on the cheek, which had been present for six months. Excision biopsy of the lesion suggested squamous carcinoma, but six months later the patient returned with enlarged submandibular nodes, which contained secondary melanoma. Staining of the primary tumour showed strong positivity with NK1 C3 (Fig. 3) .
NON-MELANOCYTIC TUMOURS

Discussion
Our results indicate that NK1 C3 can be used in a retrospective fashion to identify melanocytic cells in conventionally processed pathological specimens. The antigen identified has not as yet been characterised but the fact that it is preserved during normal processing permits use of this antibody on conventional formalin fixed and paraffin processed material. This, of course, allows for retrospective use of the antibody and obviates the need for retention of a small and possibly non-representative section of the specimen for snap freezing at the time of operation. In the case of small pigmented lesions this is obviously an important advantage.
The antibody appears to react preferentially, but not exclusively, with lesions of melanocytic derivation. The 100% positivity rate of malignant melanoma and 88% positivity rate for all melanocy-Use of NKI C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions 371 The other antibodies with which NK1 C3 can reasonably be compared include antibodies to S100 protein and neurone specific enolase (Table 3 ). In our 12 cases S100 protein antibody yielded fainter staining of fewer cells (Fig. 4) 
